Gastroparesis Epidemiology Forecast 2025-2034

A 2023 systematic review found that the standardized prevalence of gastroparesis varied widely, ranging from 13.8 to 267.7 per 100,000 adults in studies conducted between 1994 and 2019. Additionally, two community-based studies in The United States estimated the prevalence at 21.5 per 100,000 adults and 24.2 per 100,000 adults, respectively.

Gastroparesis Epidemiology Forecast Report Coverage

The Gastroparesis Epidemiology Forecast Report 2025-2034 delivers a comprehensive analysis of the condition’s prevalence and associated demographic factors. It projects future incidence and prevalence trends across diverse population groups, considering key variables such as age, gender, and gastroparesis type. The report highlights change in prevalence over time and offers data-driven forecasts based on influencing factors. Additionally, it provides an in-depth overview of the disease, along with historical and projected epidemiological data for eight key markets:

The United States, United Kingdom, France, Italy, Spain, Germany, Japan, and India.

Gastroparesis:

Disease Overview

Gastroparesis is a chronic condition where the stomach's ability to empty its contents is delayed, leading to symptoms like nausea, vomiting, bloating, and abdominal pain. It occurs when the muscles or nerves controlling the stomach are damaged, often due to conditions like diabetes, surgeries, or neurological disorders. The condition impairs digestion and can lead to malnutrition, dehydration, and weight loss. Treatment may include dietary changes, medications to promote gastric motility, and in severe cases, surgery. Management aims to alleviate symptoms and improve the quality of life for affected individuals.

Epidemiology Overview

The epidemiological analysis of gastroparesis includes comprehensive data on the patient population, covering historical trends through to current estimates and future projections across the eight major markets. The Research evaluates numerous studies to provide up-to-date and forecasted patterns in gastroparesis prevalence. This includes insights into the diagnosed patient pool, segmented by age and demographic categories.

• In The United States, prevalence estimates for gastroparesis differ depending on the methodology used. A recent analysis using insurance database records indicated a prevalence of 267.7 per 100,000 adults. In contrast, regression-based estimates suggest that up to 1.8% of the population may be affected.
• According to a 2023 systematic review, standardized prevalence figures have ranged from 13.8 to 267.7 per 100,000 adults in studies spanning 1994 to 2019. Research consistently shows that gastroparesis occurs about four times more frequently in women than in men and becomes more common with age across both genders.
• A 2022 study published in Gastroenterology identified diabetes as the leading cause of gastroparesis, accounting for 57.4% of cases - 5.7% related to type 1 diabetes and 51.7% to type 2. Other significant causes include postsurgical factors (15.0%), medication-induced cases (11.8%), and idiopathic origins (11.3%).

Gastroparesis:

Treatment Overview

Gastroparesis is a condition that impairs stomach emptying, resulting in symptoms such as nausea, vomiting, and bloating. Treatment focuses on relieving symptoms, improving gastric motility, and managing underlying causes like diabetes. Treatment approaches vary depending on severity, and may include dietary changes, medications, and, in severe cases, surgical interventions. The main goal is to enhance digestion and improve quality of life.

1. Dietary Modifications:

Managing gastroparesis often begins with changes in diet. Small, frequent meals that are low in fat and fiber can ease the digestive process. Liquid foods and pureed meals are recommended to facilitate faster gastric emptying. Avoiding carbonated beverages and foods that are difficult to digest is crucial. A dietitian may help tailor a meal plan to reduce symptoms.

2. Medications:

Prokinetic agents, like metoclopramide, are commonly prescribed to help stimulate gastric motility. These medications increase stomach contractions to facilitate faster food movement. Additionally, antiemetic drugs are used to manage nausea and vomiting. In some cases, pain relievers or antidepressants are prescribed to alleviate associated discomfort or improve gut function.

3. Gastric Electrical Stimulation:

For severe cases, gastric electrical stimulation is an option. This involves implanting a device that sends electrical impulses to the stomach muscles, helping to enhance gastric motility. This method has been shown to reduce symptoms like nausea and vomiting and improve gastric emptying in patients who do not respond well to medications.

4. Botulinum Toxin Injections:

In some cases, botulinum toxin injections are used to treat gastroparesis. The toxin is injected into the pyloric sphincter (the muscle at the stomach’s exit) to help relax the muscle, thereby promoting improved gastric emptying. This treatment is typically used when other methods have failed to provide relief.

5. Surgery:

In extreme cases where other treatments fail, surgical options may be considered. A feeding tube (jejunal tube) may be surgically placed to provide nutrition directly to the small intestine. In rare instances, a gastrectomy (removal of part or all of the stomach) may be performed. However, surgery is typically a last resort after all other options have been exhausted.

Gastroparesis:

Burden Analysis

Gastroparesis significantly impacts patients' quality of life due to its debilitating symptoms, including chronic nausea, vomiting, bloating, and early satiety. These symptoms can severely limit food intake, leading to malnutrition and weight loss. Individuals often experience fatigue, dehydration, and difficulty maintaining normal daily activities. The condition can also cause emotional distress, anxiety, and depression, given the persistent and unpredictable nature of the symptoms. In severe cases, individuals may require hospitalization or feeding tubes for nutrition. As the condition is chronic and difficult to treat, it substantially reduces overall well-being and productivity.

Key Epidemiology Trends

Epidemiological trends provide insights into the evolving patterns of diseases, helping to identify emerging health risks and inform public health policy. Here are five key epidemiological trends:

1. Increasing Incidence of Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux disease is rising globally, primarily due to lifestyle changes, including poor diet, high alcohol consumption, and sedentary behavior. Over the past few decades, there has been an increase in the prevalence of GERD, with more individuals presenting with symptoms like heartburn and regurgitation. This has been especially prominent in Western nations, where the consumption of processed foods, smoking, and obesity have exacerbated the condition. Long-term GERD can lead to complications such as esophageal cancer, which is further highlighting the need for early diagnosis and management.

2. Rise in Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are increasingly being reported worldwide. Studies suggest that the prevalence of autoimmune diseases is growing, particularly in developed countries, with rising incidences noted among women. Environmental factors such as pollution, dietary habits, and infections may play a role, but genetic susceptibility also appears to be significant. The exact cause of this upward trend remains unclear, but it is believed that improved healthcare access and better diagnostic capabilities are also leading to more diagnoses.

3. Obesity and Related Conditions

Obesity rates have skyrocketed in recent years, with a particularly concerning rise in both children and adults. The global shift towards high-calorie diets, alongside reduced physical activity, is driving the increase in obesity. As a result, conditions like type 2 diabetes, cardiovascular diseases, and certain cancers are also on the rise. Obesity is now recognized as a major contributor to the global burden of disease, with public health systems across the world facing significant challenges in controlling this growing issue. This trend is particularly alarming in low-income countries, where the availability of fast food and processed snacks has increased.

4. Mental Health Disorders

The prevalence of mental health disorders has increased globally, influenced by social, economic, and environmental factors. Conditions like anxiety, depression, and stress-related disorders are now being diagnosed more frequently than ever before. The COVID-19 pandemic exacerbated this trend, with social isolation, economic uncertainty, and health fears contributing to a spike in mental health issues. There is a growing recognition of the need for better mental health care systems and a reduction in the stigma surrounding mental illnesses. Mental health has now become a key focus for epidemiologists, especially in addressing the rising demand for psychological support and therapy.

5. Infectious Disease Resurgence

While vaccines have eradicated or controlled many infectious diseases, there has been a resurgence of several illnesses due to factors such as vaccine hesitancy, inadequate vaccination coverage, and antimicrobial resistance. Diseases like measles, tuberculosis, and pertussis have made a comeback in some regions, despite the availability of effective vaccines and treatments. Furthermore, antimicrobial resistance, exacerbated by the overuse of antibiotics, is causing many infections to become more difficult to treat. This underscores the need for renewed global efforts in disease prevention, public health infrastructure, and antibiotic stewardship.

Analysis By Region

The epidemiology of gastroparesis varies across countries and regions due to differences in healthcare infrastructure, socioeconomic factors, cultural attitudes towards pain, and access to pain management therapies. Understanding these variations is essential for developing targeted interventions and improving patient outcomes.

Key regions include:

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

These regions exhibit distinct epidemiological trends, reflecting the unique challenges and opportunities within their healthcare systems.

The epidemiology of gastroparesis differs considerably across countries, influenced by factors such as the prevalence of underlying conditions like diabetes, access to healthcare, diagnostic approaches, dietary patterns, and genetic predispositions. Additionally, public awareness, healthcare infrastructure, and socioeconomic factors also play a role in determining prevalence rates. In the United Kingdom, the diagnosed prevalence of gastroparesis was reported to be approximately 13.8 cases per 100,000 individuals.

Key Questions Answered

1. How does socioeconomic status influence the incidence and outcomes of chronic diseases in different populations?
2. What are the key factors contributing to the geographic variation in the prevalence of infectious diseases like tuberculosis or malaria?
3. How does public health infrastructure impact the detection and treatment of emerging infectious diseases in low-resource settings?
4. What role do genetic predispositions play in the global variation of non-communicable diseases such as cardiovascular diseases or diabetes?
5. How do environmental factors, like air pollution or climate change, influence the epidemiology of respiratory diseases?
6. In what ways can vaccination programs impact the epidemiology of both common and rare infectious diseases?
7. How does urbanization contribute to the rise of non-communicable diseases in rapidly developing countries?
8. What are the challenges in tracking the epidemiology of mental health disorders, and how can data collection improve?
9. How do changes in healthcare access and policies impact the prevalence of chronic conditions such as obesity or hypertension?
10. How can advanced genetic and genomic studies help refine our understanding of the epidemiology of rare diseases?

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of gastroparesis based on several factors.
• The gastroparesis epidemiology forecast report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, the unmet needs of gastroparesis are highlighted along with an assessment of the disease's risk and burden.